

Efficacy and tolerability of the non-benzodiazepine antispasmodic methocarbamol for the short-term treatment of acute low back pain over 3 days - results of a patient-level pooled re-analysis of depersonalized data from two double-blind randomized placebo-controlled clinical trials evaluating oral and intravenous use. (METABO)

**First published:** 07/12/2022

**Last updated:** 23/04/2024

Study

Ongoing

## Administrative details

### EU PAS number

EUPAS50070

---

### Study ID

50071

---

## DARWIN EU® study

No

---

### Study countries

☐ Germany

---

### Study description

Patient-level pooled re-analysis of 72-hr. data from two double-blind, randomized, placebo-controlled trials evaluation the efficacy of the non-benzodiazepine antispasmodic methocarbamol (either given intravenously or orally) vs. matching placebo in adult patients with acute low back pain.

---

### Study status

Ongoing

## Research institutions and networks

### Institutions

O.Meany-MDPM

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

## Contact details

### Study institution contact

Michael Ueberall michael.ueberall@omeany.de

Study contact

michael.ueberall@omeany.de

**Primary lead investigator**

Michael Ueberall

Primary lead investigator

## Study timelines

**Date when funding contract was signed**

Planned: 01/08/2022

Actual: 30/08/2022

---

**Study start date**

Planned: 10/10/2022

Actual: 25/11/2022

---

**Data analysis start date**

Planned: 24/10/2022

Actual: 01/12/2022

---

**Date of final study report**

Planned: 09/12/2022

## Sources of funding

- Pharmaceutical company and other private sector

- Other

## More details on funding

Recordati, Institute of Neurological Sciences

## Regulatory

### **Was the study required by a regulatory body?**

No

---

### **Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

#### **Study type:**

Non-interventional study

---

#### **Scope of the study:**

Effectiveness study (incl. comparative)

#### **Main study objective:**

The main objective of this re-analysis is to gain further insight into the differential effects of methocarbamol (given either iv or po) vs. placebo for the

immediate short-term treatment of acute low back pain in adult patients.

## Study Design

### **Non-interventional study design**

Other

---

### **Non-interventional study design, other**

Patient-level pooled re-analysis of data from studies done in the past

## Study drug and medical condition

### **Anatomical Therapeutic Chemical (ATC) code**

(M03BA03) methocarbamol

methocarbamol

---

### **Medical condition to be studied**

Back pain

## Population studied

### **Age groups**

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

---

### **Estimated number of subjects**

359

## Study design details

## Outcomes

The primary outcome of this study is the evaluation of the 72-hour response rate, based a) on the documented degree of pain relief (improvement  $\geq 20$ mm VAS and/or  $\geq 50\%$  vs. baseline), b) finger-to-floor distance (improvement  $\geq 15$ cm and/or  $\geq 50\%$  vs. baseline), c) pain-related movement restrictions (none or mild), d) Lasègue sign (negative), and e) pain-related disturbances of night sleep (none). Secondary outcomes of this study focus on the overall response to study medication for all five efficacy criteria mentioned above and all three post-baseline evaluation timepoints (24, 48, and 72 hours), percentage and timepoint of patients stopping study medication due to complete vanishing of pain, as well as premature treatment discontinuations due to adverse events, inadequate efficacy and/o

---

## Data analysis plan

Descriptive and inferential statistical analyses will be performed as reported. For continuous variables, descriptive statistics will be summarized by the number of patients (n), the mean, standard deviation (SD), 95% confidence intervals (95%-CI) of the mean, median, and range (minimum – maximum) values. For categorical and ordinal variables data will be summarized by frequency number (n), and percentage (%) of participants in each category, incl. 95% confidence intervals. For between groups comparisons of 2x2 contingency tables with a dichotomous/binomial trait the Chi-Square test will be applied, and Pearson's chi-squared tests will be used for categorial variables with multinomial expressions. Between groups comparisons of continuous variables will be applied dependent on the data distribution: for normally distributed data paired samples t-tests and for non-normal distributions Wilcoxon's signed rank test will be performed.

## Data management

## ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data sources (types)

Other

---

#### Data sources (types), other

Patient-level pooled re-analysis of already existing depersonalized raw data from two clinical trials performed in 2002/2003.

## Use of a Common Data Model (CDM)

### CDM mapping

No

## Data quality specifications

### Check conformance

Unknown

---

### Check completeness

Unknown

---

### **Check stability**

Unknown

---

### **Check logical consistency**

Unknown

## **Data characterisation**

### **Data characterisation conducted**

No